gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate has been researched along with meglumine in 26 studies
| Studies (gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate) | Trials (gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate) | Recent Studies (post-2010) (gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate) | Studies (meglumine) | Trials (meglumine) | Recent Studies (post-2010) (meglumine) |
|---|---|---|---|---|---|
| 638 | 31 | 243 | 4,168 | 413 | 1,399 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.85) | 18.7374 |
| 1990's | 3 (11.54) | 18.2507 |
| 2000's | 9 (34.62) | 29.6817 |
| 2010's | 8 (30.77) | 24.3611 |
| 2020's | 5 (19.23) | 2.80 |
| Authors | Studies |
|---|---|
| Charpentier, A; de Baere, T; di Paola, M; Shapeero, LG; Terrier, P; Vanel, D | 1 |
| Gries, H; Press, WR; Weinmann, HJ | 1 |
| Amiel, M; Baguet, J; Belleville, J; Corot, C; Eloy, R; Paul, J | 1 |
| Bautz, W; Dobritz, M; Fellner, C; Fellner, F; Janka, R; Lang, W; Lenz, M | 1 |
| Bazot, MJ; Bigot, JM; Bonneau, M; Boudghene, F; Farres, MT; Le Blanche, AF; Levy, B; Wassef, M | 1 |
| Alfieri, G; Biondi, L; Calabi, L; De Miranda, M; Ghelli, S; Paleari, L | 1 |
| Bader, CW; Froehlich, JM; Lohr, HA; Pfyffer, M; Wentz, KU; Zollikofer, CL | 1 |
| Alerci, M; Braghetti, A; Cozzi, L; Gallino, A; Gianella, S; Wyttenbach, R | 1 |
| Beaudouin, E; Blanloeil, Y; Guilloux, L; Kanny, G; Moneret-Vautrin, DA; Renaudin, JM | 1 |
| Dewey, M; Hamm, B; Kaufels, N; Kivelitz, D; Laule, M; Raynaud, JS; Robert, P; Schnorr, J; Taupitz, M; Wagner, S | 1 |
| Barreau, X; Colosimo, C; Gérardin, E; Guézénoc, F; Kirchin, MA; Knopp, MV; Lodemann, KP | 1 |
| Bilecen, D; Bongartz, G; Bremerich, J; Egelhof, T; Huegli, RW; Rasmus, M | 1 |
| Albert, A; Brauckmann, C; Günsel, A; Karst, U; Krämer, BK; Künnemeyer, J; Nowak, S; Telgmann, L; Terborg, L; Tokmak, F; Wiesmüller, GA | 1 |
| Bousquet, PJ; Cavigioli, S; Demoly, P; Galera, C; Pur Ozygit, L | 1 |
| Aliprandi, A; Di Leo, G; Papini, GD; Sardanelli, F; Secchi, F; Tritella, S | 1 |
| Burden, AD; Edward, M; Jardine, AG; Newton, BB; Quinn, JA | 1 |
| Boué, F; Bruckert, F; Combe, S; Dempsey, NM; Gaude, V; Haguet, V; Ith, A; Kauffmann, P; O'Brien, D; Reyne, G; Schaack, B | 1 |
| Chandrasekharan, P; Chuang, KH; He, T; He, Z; Liu, S; Poh, Z; Robins, EG; Yang, CT; Yong, CX | 1 |
| Engelken, FJ; Fallenberg, EM; Hamm, B; Huppertz, A; Ingod-Heppner, B; Karle, B; Reles, A; Renz, DM; Schwenke, C; Taupitz, M | 1 |
| Hartman, RP; Hunt, CH; Kallmes, DF; Kolbe, AB; Maddox, DE; McDonald, JS; McDonald, RJ; Schmitz, JJ | 1 |
| Davenport, MS; Gagnier, JJ; MacEachern, MP; Shankar, PR; Singer, L; Woolen, SA | 1 |
| Conti, A; Della Penna, S; Dumont, E; Gerstenmayer, M; Larrat, B; Le Bihan, D; Lux, F; Magnin, R; Mériaux, S; Tillement, O; Tsapis, N | 1 |
| Black, KL; Ding, H; Galstyan, A; Grodzinski, ZB; Holler, E; Israel, LL; Ljubimova, JY; Patil, R; Shatalova, ES; Wagner, S | 1 |
| Araki, Y; Kokubo, R; Kurata, C; Saito, K; Suzuki, K; Wakabayashi, Y | 1 |
| Froehlich, JM; Guirguis, N; Gutzeit, A; Koh, DM; Kolokythas, O; Matoori, S; Moussa, L; Sartoretti-Schefer, S; Wu, D | 1 |
| Blanco, C; Jiménez-Saiz, R; López-Raigada, A; López-Sanz, C; Ruiz de Azcárate, PH; Vega, F | 1 |
1 review(s) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and meglumine
| Article | Year |
|---|---|
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Topics: Contraindications, Drug; Contrast Media; Gadolinium; Glomerular Filtration Rate; Heterocyclic Compounds; Humans; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Risk; Severity of Illness Index; United States; United States Food and Drug Administration | 2020 |
6 trial(s) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and meglumine
| Article | Year |
|---|---|
Comparison of Gd-BOPTA and Gd-DOTA for peripheral CE-MRA: a double-blind clinical study.
Topics: Contrast Media; Double-Blind Method; Female; Heterocyclic Compounds; Humans; Magnetic Resonance Angiography; Male; Meglumine; Middle Aged; Organometallic Compounds; Peripheral Vascular Diseases; Prospective Studies | 2002 |
Prospective blinded evaluation of Gd-DOTA- versus Gd-BOPTA-enhanced peripheral MR angiography, as compared with digital subtraction angiography.
Topics: Adult; Aged; Aged, 80 and over; Angiography, Digital Subtraction; Contrast Media; Female; Heterocyclic Compounds; Humans; Magnetic Resonance Angiography; Male; Meglumine; Middle Aged; Organometallic Compounds; Prospective Studies; Reproducibility of Results; Single-Blind Method | 2003 |
A comparison of Gd-BOPTA and Gd-DOTA for contrast-enhanced MRI of intracranial tumours.
Topics: Aged; Brain Neoplasms; Contrast Media; Cross-Over Studies; Double-Blind Method; Female; Glioma; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Organometallic Compounds; Sensitivity and Specificity | 2004 |
Total-body contrast-enhanced MRA on a short, wide-bore 1.5-T system: intra-individual comparison of Gd-BOPTA and Gd-DOTA.
Topics: Adult; Arteries; Contrast Media; Equipment Design; Equipment Failure Analysis; Feasibility Studies; Female; Heterocyclic Compounds; Humans; Magnetic Resonance Angiography; Male; Meglumine; Middle Aged; Organometallic Compounds; Whole Body Imaging; Young Adult | 2008 |
Intraindividual, randomized comparison of the macrocyclic contrast agents gadobutrol and gadoterate meglumine in breast magnetic resonance imaging.
Topics: Adolescent; Adult; Aged; Breast Diseases; Contrast Media; Cross-Over Studies; Female; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Meglumine; Middle Aged; Organometallic Compounds; Prospective Studies; Sensitivity and Specificity; Young Adult | 2015 |
Abdominal Organ Enhancement in Dynamic MRI using 1 M Gadobutrol vs 0.5 M Meglumine Gadoterate in Liver of Hemangioma Patients.
Topics: Aorta, Abdominal; Contrast Media; Hemangioma; Heterocyclic Compounds; Humans; Liver; Magnetic Resonance Imaging; Meglumine; Organometallic Compounds | 2021 |
19 other study(ies) available for gadolinium 1,4,7,10-tetraazacyclododecane-n,n',n'',n'''-tetraacetate and meglumine
| Article | Year |
|---|---|
Osteosarcoma after chemotherapy: evaluation with contrast material-enhanced subtraction MR imaging.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Combined Modality Therapy; Contrast Media; Doxorubicin; Drug Combinations; Female; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Meglumine; Methotrexate; Organometallic Compounds; Osteosarcoma; Pentetic Acid; Remission Induction; Subtraction Technique | 1992 |
Tolerance of extracellular contrast agents for magnetic resonance imaging.
Topics: Animals; Contrast Media; Drug Combinations; Drug Tolerance; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Magnetic Resonance Imaging; Meglumine; Mice; Organometallic Compounds; Osmolar Concentration; Pentetic Acid; Rats | 1990 |
In vitro interactions of gadolinium DOTA meglumine and gadolinium DTPA meglumine on hemostasis.
Topics: Contrast Media; Gadolinium DTPA; Hemostasis; Heterocyclic Compounds; Humans; In Vitro Techniques; Magnetic Resonance Imaging; Meglumine; Organometallic Compounds; Pentetic Acid | 1988 |
Gd-BOPTA: "the MRA contrast agent of choice"?
Topics: Aortic Valve Stenosis; Chelating Agents; Contrast Media; Gadolinium; Heterocyclic Compounds; Humans; Magnetic Resonance Angiography; Meglumine; Organometallic Compounds; Subclavian Artery; Vascular Diseases | 1999 |
Evaluation of renal arteries with use of gadoterate meglumine-, CO(2)-, and iodixanol-enhanced DSA measurements versus histomorphometry in renal artery restenosis in rabbits.
Topics: Angiography, Digital Subtraction; Animals; Carbon Dioxide; Contrast Media; Disease Models, Animal; Heterocyclic Compounds; Male; Meglumine; Organometallic Compounds; Rabbits; Renal Artery; Renal Artery Obstruction; Triiodobenzoic Acids | 2001 |
Application of high-resolution magic-angle spinning NMR spectroscopy to define the cell uptake of MRI contrast agents.
Topics: Cell Membrane Permeability; Contrast Media; Erythrocytes; Fourier Analysis; Gadolinium DTPA; Heterocyclic Compounds; Humans; Leukocytes; Magnetic Resonance Spectroscopy; Meglumine; Organometallic Compounds; Tissue Distribution | 2002 |
Anaphylactic shock induced by gadoterate meglumine (DOTAREM).
Topics: Adult; Anaphylaxis; Contrast Media; Cross Reactions; Drug Hypersensitivity; Female; Gadolinium DTPA; Heterocyclic Compounds; Histamine Release; Humans; Intradermal Tests; Magnetic Resonance Imaging; Meglumine; Organometallic Compounds | 2003 |
Assessment of myocardial infarction in pigs using a rapid clearance blood pool contrast medium.
Topics: Animals; Contrast Media; Coronary Vessels; Heterocyclic Compounds; Image Enhancement; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Meglumine; Myocardial Infarction; Myocardial Reperfusion; Myocardium; Organometallic Compounds; Random Allocation; Reproducibility of Results; Swine; Swine, Miniature | 2004 |
Quantification and excretion kinetics of a magnetic resonance imaging contrast agent by capillary electrophoresis-mass spectrometry.
Topics: Adult; Contrast Media; Electrophoresis, Capillary; Gadolinium DTPA; Heterocyclic Compounds; Humans; Image Enhancement; Kinetics; Magnetic Resonance Imaging; Male; Mass Spectrometry; Meglumine; Organometallic Compounds | 2009 |
Gadoteridol-induced anaphylaxis - not a class allergy.
Topics: Aged; Anaphylaxis; Contrast Media; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Hypersensitivity; Male; Meglumine; Organometallic Compounds; Skin Tests | 2010 |
Myocardial delayed enhancement using a single dose (0.1 mmol/kg) of gadobenate dimeglumine: contrast resolution versus intraventricular blood and viable myocardium.
Topics: Contrast Media; Female; Heterocyclic Compounds; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Myocardial Infarction; Organometallic Compounds; Retrospective Studies; Statistics, Nonparametric | 2010 |
Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation.
Topics: Adult; Cell Proliferation; Collagen; Contrast Media; Dose-Response Relationship, Drug; Edetic Acid; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Hyaluronic Acid; Linear Models; Magnetic Resonance Imaging; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds | 2010 |
Diamagnetically trapped arrays of living cells above micromagnets.
Topics: Cell Culture Techniques; Cell Growth Processes; Cell Survival; Contrast Media; Equipment Design; Gadolinium; Heterocyclic Compounds; Humans; Jurkat Cells; Magnets; Meglumine; Organometallic Compounds; Tissue Array Analysis | 2011 |
Gadolinium chelate with DO3A conjugated 2-(diphenylphosphoryl)-ethyldiphenylphosphonium cation as potential tumor-selective MRI contrast agent.
Topics: Animals; Cell Line; Cell Line, Tumor; Contrast Media; Gadolinium; HeLa Cells; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Meglumine; Mice; Organometallic Compounds; Xenograft Model Antitumor Assays | 2012 |
Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections.
Topics: Acute Disease; Adult; Aged; Contrast Media; Drug Hypersensitivity; Female; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Organometallic Compounds; Retrospective Studies; Risk Factors | 2019 |
Empirical and Theoretical Characterization of the Diffusion Process of Different Gadolinium-Based Nanoparticles within the Brain Tissue after Ultrasound-Induced Permeabilization of the Blood-Brain Barrier.
Topics: Algorithms; Animals; Blood-Brain Barrier; Capillary Permeability; Contrast Media; Corpus Striatum; Diffusion; Extracellular Space; Heterocyclic Compounds; Male; Meglumine; Microbubbles; Nanoconjugates; Organometallic Compounds; Particle Size; Phantoms, Imaging; Phospholipids; Rats; Rats, Sprague-Dawley; Sulfur Hexafluoride; Ultrasonic Waves | 2019 |
Single- and Multi-Arm Gadolinium MRI Contrast Agents for Targeted Imaging of Glioblastoma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Contrast Media; Disease Models, Animal; Female; Glioblastoma; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Meglumine; Mice, Nude; Nanostructures; Organometallic Compounds; Xenograft Model Antitumor Assays | 2020 |
Comparison of gadolinium-based contrast agents for MR cholangiography in saline, blood and bile: a phantom study.
Topics: Bile; Cholangiography; Contrast Media; Gadolinium; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Meglumine | 2023 |
Meglumine gadoterate induces immunoglobulin-independent human mast cell activation via MRGPRX2.
Topics: Cell Degranulation; Humans; Immunoglobulins; Mast Cells; Meglumine; Nerve Tissue Proteins; Organometallic Compounds; Receptors, G-Protein-Coupled; Receptors, Neuropeptide | 2023 |